Skip to content
Comparison

CJC-1295 with DAC vs CJC-1295 (No DAC / Mod GRF 1-29)

CJC-1295 with DAC and CJC-1295 (No DAC / Mod GRF 1-29) are commonly compared for long-acting versus pulsatile GHRH strategy. CJC-1295 with DAC is usually favored for less frequent injections and sustained exposure, while CJC-1295 (No DAC / Mod GRF 1-29) is often preferred for physiologic pulse timing with flexible dosing. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For long-acting versus pulsatile GHRH strategy, the better choice depends on your primary endpoint. CJC-1295 with DAC is stronger when the priority is convenience-oriented schedules. CJC-1295 (No DAC / Mod GRF 1-29) is stronger when the priority is pulse-physiology optimization. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaCJC-1295 with DACCJC-1295 (No DAC / Mod GRF 1-29)
Primary mechanismLong-acting GHRH analog with albumin-binding DAC extensionShorter-acting GHRH analog favoring pulsatile GH physiology
Strongest clinical signalSustained GH/IGF-1 elevation from less frequent injectionsPulse-focused GH support, often used in combination protocols
Typical dosing context0.5-2 mg once or twice weekly100-300 mcg once to three times daily
AdministrationSubcutaneous injectionSubcutaneous injection
Evidence quality gradeModerate physiological and early clinical evidenceModerate mechanistic support
Regulatory statusNot FDA-approvedNot FDA-approved
Side-effect burdenPotential prolonged GH exposure and water retentionGenerally manageable side-effect profile
Cost/access contextModerate-to-high depending on sourceModerate cost with higher injection frequency burden
Best candidate profileUsers preferring infrequent GH secretagogue dosingProtocols prioritizing physiologic GH pulsatility
Main limitationLess physiologic pulse pattern vs no-DAC strategiesFrequent injections needed for sustained effect
Best use case in this comparisonconvenience-oriented schedulespulse-physiology optimization

When to Choose Each

Choose CJC-1295 with DAC

Best for convenience-oriented schedules.

Choose CJC-1295 (No DAC / Mod GRF 1-29)

Best for pulse-physiology optimization.

Verdict

If the main goal is convenience-oriented schedules, CJC-1295 with DAC is usually the better first-line choice. If the main goal is pulse-physiology optimization, CJC-1295 (No DAC / Mod GRF 1-29) is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006) — PubMed
  2. Effects of a chemical conjugate of growth hormone-releasing hormone with albumin on body composition in HIV-positive patients (2004) — PubMed
  3. Long-acting growth hormone releasing factor analogs: pharmacokinetics and pharmacodynamics of CJC-1295 (2007) — PubMed
  4. Growth hormone-releasing hormone analogs: chemistry and pharmacology (1999) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for long-acting versus pulsatile GHRH strategy — CJC-1295 with DAC or CJC-1295 (No DAC / Mod GRF 1-29)?
CJC-1295 with DAC is graded as moderate physiological and early clinical evidence evidence in this context, while CJC-1295 (No DAC / Mod GRF 1-29) is graded as moderate mechanistic support. In practice, strength depends on whether you prioritize convenience-oriented schedules or pulse-physiology optimization. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can CJC-1295 with DAC and CJC-1295 (No DAC / Mod GRF 1-29) be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next